DK3224253T3 - Bis(sulfonamid)-derivater og deres anvendelse som mpges-inhibitorer - Google Patents

Bis(sulfonamid)-derivater og deres anvendelse som mpges-inhibitorer Download PDF

Info

Publication number
DK3224253T3
DK3224253T3 DK15862932T DK15862932T DK3224253T3 DK 3224253 T3 DK3224253 T3 DK 3224253T3 DK 15862932 T DK15862932 T DK 15862932T DK 15862932 T DK15862932 T DK 15862932T DK 3224253 T3 DK3224253 T3 DK 3224253T3
Authority
DK
Denmark
Prior art keywords
sulphonamide
bis
derivatives
mpges inhibitors
mpges
Prior art date
Application number
DK15862932T
Other languages
English (en)
Inventor
Peter Söderman
Liselott Öhberg
Katharina Högdin
Andreas Hettman
Jesper Hallberg
Maria Ek
Johan Bylund
Johan Nord
Annika Kers
Mats A Svensson
Original Assignee
Gesynta Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gesynta Pharma Ab filed Critical Gesynta Pharma Ab
Application granted granted Critical
Publication of DK3224253T3 publication Critical patent/DK3224253T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15862932T 2014-11-27 2015-11-24 Bis(sulfonamid)-derivater og deres anvendelse som mpges-inhibitorer DK3224253T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1451436 2014-11-27
PCT/SE2015/051262 WO2016085392A1 (en) 2014-11-27 2015-11-24 Bis(sulfonamide) derivatives and their use as mpges inhibitors

Publications (1)

Publication Number Publication Date
DK3224253T3 true DK3224253T3 (da) 2019-12-09

Family

ID=56074771

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15862932T DK3224253T3 (da) 2014-11-27 2015-11-24 Bis(sulfonamid)-derivater og deres anvendelse som mpges-inhibitorer

Country Status (15)

Country Link
US (1) US10081614B2 (da)
EP (1) EP3224253B1 (da)
JP (1) JP6649538B2 (da)
CN (1) CN107001309B (da)
CY (1) CY1122561T1 (da)
DK (1) DK3224253T3 (da)
ES (1) ES2765490T3 (da)
HR (1) HRP20200043T1 (da)
HU (1) HUE047857T2 (da)
PL (1) PL3224253T3 (da)
PT (1) PT3224253T (da)
RS (1) RS59741B1 (da)
SI (1) SI3224253T1 (da)
SM (1) SMT202000024T1 (da)
WO (1) WO2016085392A1 (da)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070006890A (ko) * 2004-05-04 2007-01-11 화이자 인코포레이티드 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물
CA2620363A1 (en) * 2005-10-13 2007-04-19 Biolipox Ab Naphthalene-disulfonamides useful for the treatment of inflammation
WO2008129288A2 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
WO2008129276A1 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
TW200930369A (en) * 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
UY31468A1 (es) * 2007-11-15 2009-07-17 Derivados bis-(sulfonilamino) en terapia 065
US20090163586A1 (en) * 2007-12-20 2009-06-25 Astrazeneca Ab Bis-(Sulfonylamino) Derivatives in Therapy 205
WO2010132016A1 (en) 2009-05-14 2010-11-18 Astrazeneca Ab Bis-(sulfonylamino) derivatives for treatment of pain and inflammation
WO2011099832A2 (en) * 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
CN107001251A (zh) * 2014-11-27 2017-08-01 埃克杜鲁姆房地产有限公司 双(磺酰胺)衍生物及其作为mpges抑制剂的用途

Also Published As

Publication number Publication date
SI3224253T1 (sl) 2020-02-28
HRP20200043T1 (hr) 2020-03-20
JP6649538B2 (ja) 2020-02-19
WO2016085392A1 (en) 2016-06-02
JP2017538784A (ja) 2017-12-28
RS59741B1 (sr) 2020-02-28
EP3224253A1 (en) 2017-10-04
EP3224253A4 (en) 2018-05-09
US10081614B2 (en) 2018-09-25
US20170313672A1 (en) 2017-11-02
ES2765490T3 (es) 2020-06-09
CN107001309A (zh) 2017-08-01
PL3224253T3 (pl) 2020-05-18
HUE047857T2 (hu) 2020-05-28
PT3224253T (pt) 2020-01-20
CN107001309B (zh) 2021-03-05
SMT202000024T1 (it) 2020-03-13
EP3224253B1 (en) 2019-10-30
CY1122561T1 (el) 2021-01-27

Similar Documents

Publication Publication Date Title
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3149001T3 (da) Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
DK3221306T3 (da) Heteroarylforbindelser som irak-inhibitorer og anvendelser deraf
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3458443T3 (da) Aromatiske sulfonamidderivater
DK3663290T3 (da) Polymethinforbindelser og anvendelse deraf som fluorescerende markører
DK3204381T3 (da) N-pyridinylacetamidderivater som wnt-signaleringsbanehæmmere
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3204378T6 (da) N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
LT3164380T (lt) Lizinui specifiniai demetilazės-1 inhibitoriai
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3766885T3 (da) Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer
DK3348556T3 (da) Heteroarylamider som hæmmere af proteinaggregering
DK3341379T3 (da) EZH2-hæmmere
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3476830T3 (da) Polymethinforbindelser og anvendelse deraf som fluorescerende markører
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
EP3454852A4 (en) PHOSPHOTIDYLINOSITOL 3-KINASES INHIBITORS
DK3126354T3 (da) Halogenerede quinazolin-thf-aminer som pde1-inhibitorer